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ABSTRACT
Thrombocytopenia is often associated with clinically worse outcomes in dengue 
viral infection (DVI) patients. Histamine-2 receptor antagonist (H2RA) and 
proton pump inhibitor (PPI) have been reported to induce thrombocytopenia. 
These drugs are administered to DVI patients due to misinterpretation of 
abdominal pain. The study aimed to evaluate the correlation between H2RA 
and PPI administration with thrombocytopenia event on hospitalized DVI 
patients. An analytical retrospective cross-sectional study was conducted 
using medical records of the patient admitted by final diagnosed DVI in seven 
major hospital in Bandung from January 1st to December 31st, 2015. Patients 
were separated into two groups i.e. with and without H2RA and PPI. Pearson 
point biserial analysis was then applied to evaluate the correlation of each 
drug administration to platelet count of DVI.  A total of 4005 patients with final 
diagnosed DVI involved in this study. About 11.0% and 25.1% of the patients 
received H2RA and PPI, respectively. Mostly the DVI patients receiving H2RA 
(55%) and PPI (50.8%) showed the platelet count <50.000/mm3. A very weak 
positive correlation between the administration of H2RA (p <0.001; r=0.103) 
and PPI (p <0.001; r=0.138) with the low platelet count of the patients was 
observed. In conclusion, the administration of H2RA and PPI is correlated to 
the low platelet count in DVI patients. Although the correlation is weak, H2RA 
and PPI should be administered with caution due to its thrombocytopenia side 
effect.
ABSTRAK 
Trombositopenia sering dikaitkan dengan luaran klinik yang buruk pada 
pasien infeksi virus dengue (IVD). Histamine-2 receptor antagonist (H2RA) dan 
proton pump inhibitor (PPI) dilaporkan dapat menyebabkan trombositopenia. 
Obat ini diberikan pada pasien IVD karena misinterpretasi gejala nyeri 
abdomen pasien. Penelitian ini bertujuan untuk mengkaji hubungan antara 
pemberian H2RA dan PPI dengan kejadian trombositopenia pada pasien rawat 
inap IVD. Penelitian ini merupakan penelitian potong lintang analitik dengan 
pendekatan restrospektif menggunakan data rekam medis pasien rawat inap 
yang terdiagnosis akhir IVD di tuju rumah sakit utama di Bandung periode 
1 Januari sampai 31 Desember 2015. Pasien dikelompokkan ke dalam dua 
kelompok yaitu tanpa dan dengan pemberian H2RA dan PPI. Analisis poin 
biserial Pearson dilakukan untuk mengkaji hubungan antara pemberian 
masing-masing obat terhadap jumlah trombosit pasien IVD. Sebanyak 4005 
pasien dengan diagnosis akhir IVD terlibat dalam penelitian. Sebanyak 11.0% 
dan 25.1% pasien menerima secara berturut-turut H2RA dan PPI. Sebagian 
besar pasien yang menerima H2RA (55.0%) dan PPI (50.8%) menunjukkan 
jumlah trombosit <50.000/mm3. Terdapat hubungan positif lemah antara 
pemberian H2RA (p <0,001; r=0,103) and PPI (p <0,001; r=0,138) dengan jumlah 
trombosit yang rendah. Simpulan, pemberian H2PA dan PPI berhubungan 
dengan jumlah trombosit yang rendah pada IVD. Meskipun hubungannya 
lemah, pemberian H2PA dan PPI harus menjadi perhatian karena efek samping 
trombisitopenianya.
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INTRODUCTION
Dengue viral infection (DVI) is a 
common arboviral disease in humans 
that remains to be a global burden 
in tropic and subtropics countries 
in the world.1 Dengue viral infection 
is characterized by hematologic 
abnormality presentation, namely, 
thrombocytopenia. Thrombocytopenia 
is one indicator of clinical severity which 
indirectly showed the activity of platelet 
activation. It is also counted to be a 
risk predictor for disease progression 
and prognosis in DVI.2–4 Furthermore, 
severe thrombocytopenia (<50.000/mm3) 
was independently and significantly 
associated with the risk of mortality.4
According to the World Health 
Organization (WHO) guideline, DVI 
patients can be administered some 
symptomatic therapy such as an 
antiulcer for gastrointestinal bleeding.1 
Empirically, antiulcer administration 
in the form histamine-2 receptor 
antagonist (H2RA) and proton pump 
inhibitor (PPI)5 become management 
for abdominal pain in DVI while this 
symptom was mostly manifested as the 
result of liver disturbance.6 Moreover, 
these drugs was reported as one of the 
most drugs prescribed for DVI patients 
followed analgesic, multivitamin and 
antipyretic. However, H2RA and PPI were 
reported can induce thrombocytopenia 
event7,8 which could worsen the 
thrombocytopenia condition of DVI 
patients. In this study,  the relationship 
between the administration of H2RA and 
PPI and the lowest platelet counts in DVI 
patients was reported.
MATERIALS AND METHODS 
Patients
This study is part of the Hospital-
Based Dengue Case Surveillance in 
the Municipality of Bandung, West 
Java, Indonesia in 2015. This analytical 
retrospective cross-sectional study was 
conducted using medical records of 
the patient admitted by final diagnosed 
DVI in seven major hospital in Bandung 
from January 1st to December 31st, 
2015. The hospitals involved were 
Dr. Hasan Sadikin Teaching Hospital, 
St. Borromeous Hospital, Adventist 
Hospital, St. Yusuf Hospital, Hermina 
Mother and Child Hospital Pasteur, 
Limijati Mother and Child Hospital, and 
Hermina Arcamanik Hospital.
This study included both children and 
adults which admitted to those hospitals 
with a final diagnosis confirmed as DF, 
DHF, and DSS based on WHO-SEARO 
2011 criteria.5 Patient with incomplete 
platelet examination, no information of 
final diagnosis was excluded. This study 
used total sampling, then collected data 
were grouped based on the demographic 
characteristic of sex, age group,6 and 
final diagnosis. 
Protocol of study
The patients were divided 
into groups that received and did not 
receive reduced acid secretion drugs 
(RASDs) during their admission. The 
output of each group was assessed 
by the lowest platelet count obtained 
from platelet examination during the 
admission period which was classified 
in an interval manner.7 The operational 
definitions used in this case are drugs 
that cause a reduction in gastric acid 
secretion, limited to H2RA and PPI and 
platelet counts, which were the lowest 
platelet counts during the treatment 
period. The lowest platelet value 
was selected in consideration that in 
dengue patients there was a tendency 
to have thrombocytopenia during the 
course of the disease.8 Therefore, this 
thrombocytopenia-only condition may 
be caused by DVI. This study tried to 
evaluate  the correlation whether the 
lowest platelet values in patients who 
received RASD compared to those who did 
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not receive RASD during their treatment 
period were related to drugs or not. The 
study had passed the ethical clearance by 
the Research Ethics Committee, Faculty 
of Medicine, Universitas Padjadjaran, 
Bandung.
Statistical analysis
Statistics software SPSS version 
25 was used for data analysis. Point 
biserial analysis was used to evaluate 
the relationship of each H2RA and PPI 
administration with the lowest platelet 
count in DVI patients. The p value <0.05 
was considered to be a statistically 
significant between tested variables. The 
power of relation interpreted as very 
weak (r= 0.00-0.199), weak (r=0.2-0.299), 
moderate (r=0.4-0.599), strong (r=0.6-
0.799) and very strong (r=0.8-1).9
RESULTS
A total of 4005 patients who lived in 
Bandung had admitted to the hospital by 
final diagnosed DVI were involved in this 
study. TABLE 1 shows the characteristic 
of DVI patients demographically and its 
final diagnosis group. Majority patient 
was male, accounting for 50.4% of 
all cases. The patient also dominated 
respectively by teenagers (12-25) 
accounting for 31.7%. The most DVI 
event consecutively was DHF, DF and, 
DSS.












•	Dengue fever 1459 (36.4)
•	Dengue hemorrhagic fever 2420 (60.4)
•	Dengue shock syndrome 126 (3.1)
The types of drugs given by the 
hospital to DVI patients in managing 
the cases were described based on its 
therapy class in TABLE 2. The most drug 
prescribed was analgesic-antipyretic, 
followed by antibiotics then each H2RA 
and PPI  (FIGURE 1). Some different 
characteristic of patients received H2RA 
and PPI are showed in TABLE 3. Both 
patient received H2RA and PPI were 
mostly female and patients with final 
diagnose DHF. The H2RA was mostly 
prescribed in Child accounted 51% of all 
cases, while PPI was more prescribed in 
adults, in the age group teenager age 12-
25 years old (48.0%). 
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FIGURE 1. List of prescribed drugs in DVI patients
TABLE 3. Characteristic of patients received H2RA and PPI
Characteristic
PPI H2RA
n (%) n (%)
Gender
•	Male 463 (46.1) 212 (48.0)
•	Female 541 (53.9) 230 (52.0)
Age (years old)
•	0-5 35 (3.0) 104 (24.0)
•	6-11 179 (18.0) 224 (51.0)
•	12-25 476 (48.0) 107 (24.0)
•	26-45 309 (31.0) 42 (9.0)
•	>45 120 (12.0) 19 (5.0)
Final diagnosis
•	Dengue fever 251 (25.0) 143 (32.0)
•	Dengue hemorrhagic fever 729 (73.0) 255 (58.0)
•	Dengue shock syndrome 24 (2.0) 44 (10.0)
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<50.000 50.000 - <100.000 100.000 - <150.000 ≥150000
H2RA
243 128 52 19
Yes 55.00% 29.00% 11.80% 4.30%
15.10% 9.40% 7.10% 6.40%
1369 1239 678 277
No 38.40% 34.80% 19.00% 7.80%
84.90% 90.60% 92.90% 93.60%
PPI
510 316 142 36
Yes 50.80% 31.50% 14.10% 3.60%
31.60% 23.10% 19.50% 12.20%
1102 1051 588 260
No 36.70% 35.00% 19.60% 8.70%
68.40% 76.90% 80.50% 87.80%
The low platelet counts during 
hospital admission based on H2RA and 
PPI status showed in TABLE 4. There 
was 11% of all patients who received 
H2RA and 25.1% received PPI during 
their admission to the hospital showed 
in TABLE 2. Each of the group received 
RASD and not received, was dominated by 
patients with low platelet count <50.000/
mm3, even though mostly in a group of 
patients received RASD dominated by low 
platelet count <50.000/mm3, accounted 
in chronological order for H2RA and PPI, 
55% and 50.8%, respectively. 





The relation of each of RASD group, 
specifically H2RA and PPI with patient 
low platelet count is showed in TABLE 
4. Administration of H2RA significantly 
was correlated with low platelet count 
(p<0.05), although it was classified 
very weak (r=0.103). Furthermore, 
administration of PPI was also correlated 
with low platelet count (p<0.05) with 
very weak correlation (r=0.138).
DISCUSSION
Dengue viral infection is a common 
mosquito vector-borne disease in 
humans. This study presented the drug 
utilization in managing DVI. Group of 
antiulcer (RASD) ranked the third most 
drug prescribed of the hospital, PPI 
(25.1%) and H2RA (11%) respectively, 
following analgesic-antipyretic and 
antibiotic. A retrospective study 
conducted in Yogyakarta also obtained 
similar results.10 The provision of this 
administration based on complaints 
of abdominal pain of DVI patients, 
other than to prevent the occurrence of 
gastrointestinal bleeding.1
This study found that about 11% of 
DVI patients were given H2RA during 
their admission. Most of the DVI patients 
had low platelet counts <50.000 /mm3. 
However, only 15% of all low platelet 
group patients <50.000/mm3, which 
considered severe thrombocytopenia, 
received H2RA. This large number of 
patients with severe thrombocytopenia 
despite not prescribed H2RA could 
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occur as a result of thrombocytopenia 
caused by the dengue virus itself. 
Thrombocytopenia is a manifestation 
that often occurs in patients with 
DVI. Dengue virus could cause 
thrombocytopenia by increasing platelet 
destruction via immune reactions and 
releasing inflammatory mediators 
that could interfere with the process of 
platelet production.11,12
Previous studies reported that 
thrombocytopenia could be induced 
by RASDs, although this event is 
still considered a relatively rare 
phenomenon. The evidence of H2RA 
induced thrombocytopenia events was 
confirmed by finding the presence of 
drug-dependent-antibodies (DDA) in 
the serum of patients who had severe 
acute thrombocytopenia after receiving 
H2RA.
13 These antibodies formed due to 
H2RA, which even in pharmacological 
concentrations, were able to recognize 
the receptor side of GPIX platelet so that 
they can destroy platelets and cause 
thrombocytopenia. Reese et al.14 also 
analyzed the drugs that cause acute 
hospital-acquired thrombocytopenia in 
hospitalized patients using 3 different 
methods to reassert the truth of this 
incident. The results showed that the 
H2RA can cause thrombocytopenia 
based on clinical data extraction in 
various case reports, data mining and 
proven by the presence of antibodies 
on laboratory examination. Arnold et 
al.15 also reinforced the occurrence of 
H2RA induced thrombocytopenia. The 
study identified drugs that clinically 
caused the incidence of drug-induced 
thrombocytopenia (DITP) included H2RA. 
Although those studies had proved the 
incidence of thrombocytopenia induced 
by H2RA. However, all those study were 
involved non-DVI patients. Until now, the 
studies reporting the thrombocytopenia 
induced by H2RA administration in DVI 
patients are limited. This study reported 
the positive significant correlation 
between H2RA and low platelet counts 
in DVI patients, although the correlation 
was considered very weak.
This study found about 25.1% of 
patients with DVI received PPIs during 
their admission and most (55%) had 
platelet counts <50.000/mm3 or severe 
thrombocytopenia. Thrombocytopenia 
is known not to be a common side effect 
of PPI drugs. Nevertheless, this study 
showed a positive significant correlation 
with very weak strength. Surprisingly, 
that PPI had a stronger relationship with 
thrombocytopenia than H2RA. This could 
occur since H2RA has been more known 
to be able to cause thrombocytopenia so 
that its use was less than PPI.
Previous studies also reported 
the decreasing platelet following 
PPI administration. Aster et al.16 
showed that the PPI group can induce 
thrombocytopenia occurrence. Various 
PPI classes were also reported in some 
case reports and reviews of literature.17,18 
Retrospective analytic studies conducted 
at Duke University Hospital also found 
an significantly association between 
thrombocytopenia events in hospitalized 
patients who received PPIs during their 
treatment period.19 However, these 
studies were conducted in patients 
with acute thrombocytopenia during 
their admission period not DVI patients. 
Although many studies support the 
relationship between PPI administration 
and thrombocytopenia, this phenomenon 
was still based on the analysis of 
various case reports and retrospective 
studies. Therefore, a prospective study 
is required to confirm this relationship, 
even less, in DVI patients. 
This study has several limitations. 
First, this study also did not regard the 
coinfection of patients which might be 
another cause of thrombocytopenia. 
Second, in the obtained data, there was 
no information regarding the timing of 
starting the drug and the daily platelet 
value of each patient. Subsequently, 
this study also did not adjust the 
confounding variables thus that it can 
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not be known which factors influence 
RASD administration and platelet count 
in DVI patients. Third, as this study 
used a retrospective approach with a 
cross-sectional method, the incidence 
of thrombocytopenia by the patients 
receiving RASD cannot be distinguished 
from the incidence of thrombocytopenia 
that occurs as a result of DVI itself. The 
limitation of available data regarding 
the time of RASDs administration, that 
it is inconvenient to decide the causal 
precede the effect. Further, prospective 
studies are needed to better understand 
the cause-effect of RASD administration 
on the platelet count.
CONCLUSION
In conclusion, the administration 
of H2RA and PPI is correlated to the low 
platelet count in DVI patients. Although 
the correlation is weak, H2RA and PPI 
should be administered with caution due 
to its thrombocytopenia side effect.
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